The Valley Desk

NCT04422912 · Interventional trial

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

Overall registry status Recruiting

Phase 1 · Phase 2

Conditions Pemphigus Vulgaris

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov